img

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 320 | Industry : Medical Care

Publisher : GRD Survey | Format : PDF

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.

This report studies the B-Cell Maturation Antigen(BCMA) Targeted Therapies market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells

Market Snapshot, By Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others

Main Market Players Analyzed in this report, including
Transposagen Biopharmaceuticals
Sutro Biopharma
Onyx Pharmaceuticals
Malin Corporation
Juno Therapeutics
Five Prime Therapeutics
firstVentury Equity
Eureka Therapeutics
Deerfield Partners
Dana-Farber Cancer Institute
Credit Suisse Securities

The study objectives of this report are
To study and analyze the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global B-Cell Maturation Antigen(BCMA) Targeted Therapies manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the B-Cell Maturation Antigen(BCMA) Targeted Therapies market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of B-Cell Maturation Antigen(BCMA) Targeted Therapies submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of B-Cell Maturation Antigen(BCMA) Targeted Therapies are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and B-Cell Maturation Antigen(BCMA) Targeted Therapies

3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Liver Cancer
3.2.2 Major Buyers in Respiratory Cancer

4 Market Segment: by Type
4.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Type Introduction
4.1.1 Bispecific Antibodies
4.1.2 Antibody Drug Conjugates
4.1.3 Chimeric Antigen Receptor T-Cells
4.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Type 2016-2021

5 Market Segment: by Application
5.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Type Introduction
5.1.1 Liver Cancer
5.1.2 Respiratory Cancer
5.1.3 Brain Cancer
5.1.3 Others
5.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Application 2016-2021

6 Marke Segment: by Region
6.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Region
6.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2016-2021
6.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2016-2021
6.4 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2016-2021
6.5 South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2016-2021
6.6 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2016-2021

7 North America
7.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Transposagen Biopharmaceuticals
12.1.1 Transposagen Biopharmaceuticals Company Information
12.1.2 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.1.4 Transposagen Biopharmaceuticals Key Development
12.2 Sutro Biopharma
12.2.1 Sutro Biopharma Company Information
12.2.2 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.2.4 Sutro Biopharma Key Development
12.3 Onyx Pharmaceuticals
12.3.1 Onyx Pharmaceuticals Company Information
12.3.2 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.3.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.3.4 Onyx Pharmaceuticals Key Development
12.4 Malin Corporation
12.4.1 Malin Corporation Company Information
12.4.2 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.4.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.4.4 Malin Corporation Key Development
12.5 Juno Therapeutics
12.5.1 Juno Therapeutics Company Information
12.5.2 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.5.3 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.5.4 Juno Therapeutics Key Development
12.6 Five Prime Therapeutics
12.6.1 Five Prime Therapeutics Company Information
12.6.2 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.6.4 Five Prime Therapeutics Key Development
12.7 firstVentury Equity
12.7.1 firstVentury Equity Company Information
12.7.2 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.7.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.7.4 Five Prime Therapeutics Key Development
12.9 Deerfield Partners
12.9.1 Deerfield Partners Company Information
12.9.2 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.9.4 Deerfield Partners Key Development
12.8 Eureka Therapeutics
12.8.1 Eureka Therapeutics Company Information
12.8.2 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.8.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.8.4 Eureka Therapeutics Key Development
12.11 Credit Suisse Securities
12.11.1 Credit Suisse Securities Company Information
12.11.2 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
12.11.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
12.11.4 Credit Suisse Securities Key Development

13 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Forecast by Region by Type and by Application
13.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Forecast 2022-2027
13.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast by Regions
13.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast by Type
13.4 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast by Application

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Production Specifications
Table 2: Drivers in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
Table 3: Restraints B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
Table 4: Opportunity in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
Table 5: Comparion of Alternative and B-Cell Maturation Antigen(BCMA) Targeted Therapies
Table 6: B-Cell Maturation Antigen(BCMA) Targeted Therapies Raw Materials Key Suppliers List
Table 7: B-Cell Maturation Antigen(BCMA) Targeted Therapies Distributors List
Table 8: B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Buyers in Application One
Table 9: B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Buyers in Application Two
Table 10: B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Buyers in Application Three
Table 11: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Type 2016-2021
Table 12: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type 2016-2021
Table 18: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Application 2016-2021
Table 19: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Application 2016-2021
Table 20: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Region 2016-2021
Table 21: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region 2016-2021
Table 22: North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Country 2016-2021
Table 23: North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country 2016-2021)
Table 24: Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Country 2016-2021
Table 25: Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country 2016-2021)
Table 26: Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Country 2016-2021
Table 27: Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country 2016-2021)
Table 28: South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Country 2016-2021
Table 29: South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country 2016-2021)
Table 30: Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Country 2016-2021
Table 31: Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country 2016-2021)
Table 32 Transposagen Biopharmaceuticals Company Information
Table 33 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 34 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 35 Sutro Biopharma Company Information
Table 36 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 37 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 38 Onyx Pharmaceuticals Company Information
Table 39 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 40 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 41 Malin Corporation Company Information
Table 42 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 43 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 44 Juno Therapeutics Company Information
Table 45 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 46 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 47 Five Prime Therapeutics Company Information
Table 48 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 49 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 50 firstVentury Equity Company Information
Table 51 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 52 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 53 Eureka Therapeutics Company Information
Table 54 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 55 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 56 Deerfield Partners Company Information
Table 57 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Portfolio, Specification and Application
Table 58 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Gross Margin (2019-2021)
Table 59: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Region (2022-2027)
Table 60: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Region (2022-2027)
Table 61: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Type (2022-2027)
Table 62: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Type (2022-2027)
Table 63: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Application (2022-2027)
Table 64: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: B-Cell Maturation Antigen(BCMA) Targeted Therapies Picture
Figure 2: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Life Cycle
Figure 5: Product Picture of Bispecific Antibodies
Figure 6: Product Picture of Antibody Drug Conjugates
Figure 9: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type, 2020
Figure 10: B-Cell Maturation Antigen(BCMA) Targeted Therapies in Liver Cancer
Figure 11: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market: Liver Cancer 2016-2021
Figure 12: B-Cell Maturation Antigen(BCMA) Targeted Therapies in Respiratory Cancer
Figure 13: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market: Respiratory Cancer 2016-2021
Figure 14: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Application, 2020
Figure 15: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region 2016-2021
Figure 16: North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 7: Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 8: Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 9: South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 10: Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 11: North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country, 2020
Figure 12: United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 13: Canada B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 14: Mexico B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 15: Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country, 2020
Figure 16: Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 17: France B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 18: UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 19: Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 20: Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 21: Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country, 2020
Figure 23: China B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 24: Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 25: Korea B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 26: Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 27: India B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 28: Australia B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 29: South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country, 2020
Figure 30: Brazil B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 31: Argentina B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 32: Colombia B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 33: Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Country, 2020
Figure 34: Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 35: Saudi Arabia B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 36: South Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status 2016-2021
Figure 37: Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 38: Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 39: Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 40: Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 41: Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 42: Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 43: firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 44: Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 45: Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 46: Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Globally (2019-2021)
Figure 47: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast (2022-2027)